Table 2.
Cardiac biomarkers
| Parameter |
Control group (n = 22) (controls) |
HIV‐infected ART‐naïve (n = 73) (naïve) |
P value a |
HIV‐infected 9 months on ART (n = 73) (ART) |
P value b |
Change (Δ) in HIV group over time (n = 73) |
|---|---|---|---|---|---|---|
| hs‐cTnT (ng/L) | 4.0 ± 1.3 | 5.1 ± 2.1 | 0.004 | 4.3 ± 1.5 | 0.02 | 0 (−1.0 to 0.8) |
| NT‐proBNP (ng/L) | 23.2 ± 2.3 | 40.8 ± 2.9 | 0.02 | 28.5 ± 2.5 | 0.03 | −10.0 (−36.5 to 22.3) |
| sST2 (ng/mL) | 13.4 ± 1.5 | 16.5 ± 1.7 | 0.11 | 14.8 ± 1.7 | 0.08 | −2.2 (−6.5 to 1.4) |
| Galectin‐3 (ng/mL) | 6.8 ± 1.2 | 9.0 ± 1.5 | 0.002 | 8.8 ± 1.3 | 0.6 | 0.1 (−1.4 to 1.6) |
ART, antiretroviral therapy; HIV, human immunodeficiency virus; hs‐cTnT, high‐sensitivity cardiac troponin T; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; sST2, soluble ST2.
Continuous data are presented as geometric mean ± standard deviation. Change in parameters (ART value minus naïve value) is presented as median (first quartile to third quartile). P values in bold indicate statistical significance.
a
Controls vs. ART‐naïve group compared with log10‐transformed variables.
b
ART‐naïve group vs. ART group compared with log10‐transformed variables.